S(+)-Flurbiprofen Shows Potent PGE2 Inhibitory Activity in Inflammatory Cells, Superior Cell Transport Activity and Skin Permeability
- 1 Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
- 2 Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
- 3 Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
- 4 Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
- 5 Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
- 6 Research Department, Tokuhon Corporation, Saitama, Japan
- 7 Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
- 8 Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
- 9 Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan
Abstract
We developed a novel topical non-steroidal anti-inflammatory drug (NSAID)patch, S(+)-flurbiprofen plaster, (SFPP), containing S(+)-flurbiprofen (SFP), an enantiomer of flurbiprofen (FP). In a previous study conducted in an animal model, we showed good skin absorption and potent analgesic efficacy of SFPP. In this study, to examine the superior features, as an NSAID patch, of SFP as compared to FP and R(-)-flurbiprofen (RFP), we tested the stereospecificity of SFP actions on Prostaglandin E2 (PGE2) inhibition in rat inflammatory leukocytes and in the binding activity of the drug to cells, and also the in vitro skin permeability of the drug in the Yucatan micropig (YMP). SFP showed potent inhibitory activity on PGE2 production from peritoneal leukocytes stimulated with a bacterial suspension, as compared to RFP and FP. The half maximal (50%) inhibitory concentration (IC50) values were 14 nM for SFP, 52 nM for FP, and 17,000 nM for RFP. In the cell binding study, significant and rapid increase of SFP binding to polymorphonuclear leucocytes (PMNs) was observed at 5 min after incubation, eventually reaching a steady state. SFP showed significantly higher binding activity for the inflammatory leucocytes as compared to RFP, suggesting its superior transfer potency. The skin permeability profile of SFP, RFP and FP in the YMP model showed that the rank order of the cumulative amount of permeated compounds in the skin was SFP > RFP > FP. The steady-state permeation rate (Flux) of SFP was significantly higher than that of FP (4.89 and 1.55 mg/cm2/h, respectively, p = 0.0068), indicating the remarkably superior skin permeability of SFP. SFP exerted potent inhibitory activity on PGE2 production and superior binding activity to the PMNs and skin permeability, as compared to FP and RFP. These results suggest that SFP possesses favorable characteristics for use as an active ingredient in the NSAID patch.
- Narumiya, S., Sugimoto, Y. and Ushikubi, F. (1999) Prostanoid Receptors: Structures, Properties, and Functions. Physiological Reviews, 79, 1193-1226.
- Rannou, F., Pelletier, J.P. and Martel-Pelletier, J. (2016) Efficacy and Safety of Topical NSAIDs in the Management of Osteoarthritis: Evidence from Real-Life Setting Trials and Surveys. Seminars in Arthritis and Rheumatism, 45, S18-S21. http://dx.doi.org/10.1016/j.semarthrit.2015.11.007
- Mason, L., Moore, R.A., Edwards, J.E., Derry, S. and McQuay, H.J. (2004) Topical NSAIDs for Chronic Musculoskeletal Pain: Systematic Review and Meta-Analysis. BMC Musculoskeletal Disorders, 5, 28. http://dx.doi.org/10.1186/1471-2474-5-28
- Peskar, B.M., Kluge, S., Peskar, B.A., Soglowek, S.M. and Brune, K. (1991) Effects of Pure Enantiomers of Flurbiprofen in Comparison to Racemic Flurbiprofen on Eicosanoid Release from Various Rat Organs ex Vivo. Prostaglandins, 42, 515-531. http://dx.doi.org/10.1016/0090-6980(91)90014-7
- Carabaza, A., Cabré, F., Rotllan, E., Gómez, M., Gutiérrez, M., García, M.L. and Mauleón, D. (1996) Stereoselective Inhibition of Inducible Cyclooxygenase by Chiral Nonsteroidal Antiinflammatory Drugs. The Journal of Clinical Pharmacology, 36, 505-512. http://dx.doi.org/10.1002/j.1552-4604.1996.tb05040.x
- Sugimoto, M., Toda, Y., Hori, M., Mitani, A., Ichihara, T., Sekine, S., Hirose, T., Endo, H., Futaki, N., Kaku, S., Otsuka, N. and Matsumoto, H. (2016) Analgesic Effect of the Newly Developed S(+)-Flurbiprofen Plaster (SFPP) on Inflammatory Pain in a Rat Adjuvant-Induced Arthritis Model. Drug Development Research, 77, 20-28. http://dx.doi.org/10.1002/ddr.21288
- Yataba, I., Otsuka, N., Matsushita, I., Kamezawa, M., Yamada, I., Sasaki, S., Uebaba, K., Matsumoto, H. and Hoshino, Y. (2016) Plasma Pharmacokinetics and Synovial Concentrations of S-Flurbiprofen Plaster in Humans. European Journal of Clinical Pharmacology, 72, 53-59. http://dx.doi.org/10.1007/s00228-015-1960-6
- Di Rosa, M. and Persico, P. (1979) Mechanism of Inhibition of Prostaglandin Biosynthesis by Hydrocortisone in Rat Leucocytes. British Journal of Pharmacology, 66, 161-163. http://dx.doi.org/10.1111/j.1476-5381.1979.tb13659.x
- Smith, R.J. (1978) Nonsteroid Anti-Inflammatory Agents: Regulators of the Phagocytic Secretion of Lysosomal Enzymes from Guinea-Pig Neutrophils. Journal of Pharmacology and Experimental Therapeutics, 207, 618-629.
- Matsumoto, Y., Ohsako, M. and Noda, F. (1989) Transport of Drugs through Human Erythrocyte Membrane in Vitro. Yakuzaigaku, 49, 59-63.